Today Future Science Group announces the publication of an article in Future Virology highlighting the clinical complications associated with antiretroviral therapy in Chinese HIV/ Tuberculosis (TB) coinfected patients.
In HIV infected individuals, coinfection with TB advances HIV to AIDS. As per the recommended guidelines by the Centre of Disease Control and Prevention, it is advised that these patients receive anti-tubercular treatment followed by timely initiation of combination antiretroviral therapy.
"Despite the availability of the National Free Antiretroviral Treatment Program in China, HIV-related opportunistic infections continue to cause mortality in Chinese HIV-infected individuals due to lack of awareness of HIV infection until opportunistic infections become the first indicator of their disease" explained the authors (Huarun-WISCO Hospital and Beijing Shijitan Hospital, China).
In this investigation, the authors set to identify the aetiology of clinical complications associated with this coinfection by retrospectively studying 180 HIV-infected patients admitted to the Beijing Ditan Hospital from January 2012 to April 2014. Amongst the most frequent complications were AIDS-defining illnesses with a prevalence of 20%.
There are hopes that these findings will help educate physicians treating patients with HIV/ Tuberculosis especially after initiating combination antiretroviral therapy.
Commissioning Editor for Future Virology, Frances Adlam commented: "This study addresses the important clinical problem of continued high mortality in HIV/TB coinfected patients and contains data especially applicable to resource limited settings."
###
To read the full article please click here - http://www.futuremedicine.com/doi/full/10.2217/fvl-2016-0102
About Future Virology
Launched in 2006, the journal Future Virology is part of the Future Medicine journal collection. Future Virology (impact factor: 0.886) features the latest updates in virology, infectious disease and immunology analysis, with an international Editorial Board headed by Editor-in-Chief Mark Wainberg (McGill AIDS Centre, Canada).
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com
Journal
Future Virology